Tirofiban in Stenting for Long Coronary Lesion

• Status: Completed
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Periprocedural myonecrosis or infarction are associated with short, intermediate, and long term adverse outcomes. Previous study indicated 12.6% of patients suffered a peri-procedural CK-MB rise by overlapping use of drug-eluting stents for long coronary lesions. Here the investigators hypothesize that peri-procedural use of tirofiban could reduce the occurrence of periprocedural infarciton in elective patients with long coronary lesions treated by overlapping use of drug-eluting stents.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Jiao Tong University School of Medicine
• Treatments: Tirofiban

Criteria

Inclusion Criteria:

• Age between 18y~80y, with symptomatic coronary disease

• At least one lesion length more than 40mm to be treated by overlapping drug-eluting stents in major epicardial coronary vessel

Exclusion Criteria:

• Aspirin or clopidogrel intolerance

• Lesions length less than 40mm, or overlapping stent length less than 40mm

• Bifurcation lesions need to be treated by two stents

• Patients with acute coronary syndrome and elevated baseline cardiac enzyme (CK-MB)

• Left ventricular ejection fraction less than 0.35

• Baseline estimated GFR less than 30

• Estimated life time less than one year

• Refuse to sign the informed consent